{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T09:25:21Z","timestamp":1780565121861,"version":"3.54.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1007\/s00228-017-2216-4","type":"journal-article","created":{"date-parts":[[2017,2,23]],"date-time":"2017-02-23T23:17:42Z","timestamp":1487891862000},"page":"593-600","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["No clinically meaningful pharmacokinetic interaction between the hepatitis C virus inhibitors elbasvir and grazoprevir and the oral contraceptives ethinyl estradiol and levonorgestrel"],"prefix":"10.1007","volume":"73","author":[{"given":"William L.","family":"Marshall","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hwa-Ping","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luzelena","family":"Caro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Talaty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zifang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobi","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Panebianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Mangin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry E.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan R.","family":"Butterton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy W.","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,24]]},"reference":[{"key":"2216_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","volume":"17","author":"D Lavanchy","year":"2011","unstructured":"Lavanchy D (2011) Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 17:107\u2013115","journal-title":"Clin Microbiol Infect"},{"key":"2216_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.7150\/ijms.3.47","volume":"3","author":"SL Chen","year":"2006","unstructured":"Chen SL, Morgan TR (2006) The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 3:47\u201352","journal-title":"Int J Med Sci"},{"key":"2216_CR3","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1002\/hep.27950","volume":"62","author":"AASLD\/IDSA HCV Guidance Panel","year":"2015","unstructured":"AASLD\/IDSA HCV Guidance Panel (2015) Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology 62:932\u2013954","journal-title":"Hepatology"},{"key":"2216_CR4","unstructured":"Merck & Co., Inc. (2016) Zepatier\u2122 (elbasvir and grazoprevir): US prescribing information https:\/\/www.merck.com\/product\/usa\/pi_circulars\/z\/zepatier\/zepatier_pi.pdf. Accessed on 8 Sept 2016"},{"key":"2216_CR5","unstructured":"Zepatier [elbasvir\/grazoprevir] European Medicines Agency (2016) http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Summary_for_the_public\/human\/004126\/WC500211238.pdf. Accessed 19 Oct 2016"},{"key":"2216_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7326\/M15-0785","volume":"163","author":"S Zeuzem","year":"2015","unstructured":"Zeuzem S, Ghalib R, Reddy KR, Pockros PR, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen B-Y, Robertson MN, Wahl J, Barr E, Butterton JR (2015) Grazoprevir\u2013elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic HCV genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med 163:1\u201313","journal-title":"Ann Intern Med"},{"key":"2216_CR7","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jhep.2015.04.009","volume":"63","author":"X Forns","year":"2015","unstructured":"Forns X, Gordon SC, Zuckerman E, Lawitz E, Calleja JL, Hofer H, Gilbert C, Placza J, Howe AYM, DiNubile MJ, Robertson MN, Wahl J, Barr E, Buti M (2015) Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. J Hepatol 63:564\u2013572","journal-title":"J Hepatol"},{"key":"2216_CR8","doi-asserted-by":"publisher","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","volume":"2","author":"JK Rockstroh","year":"2015","unstructured":"Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen B-YT, Barr E, Platt HL, Robertson MN, Sulkowski M (2015) Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV 2:e319\u2013e327","journal-title":"Lancet HIV"},{"key":"2216_CR9","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1016\/S0140-6736(15)00349-9","volume":"386","author":"D Roth","year":"2015","unstructured":"Roth D, Nelson DR, Bruchfeld A, Liapakis AM, Silva M, Monsour H Jr, Martin P, Pol S, Londo\u00f1o M-C, Hassanein T, Zamor PJ, Zuckerman E, Wan S, Jackson B, Nguyen B-Y, Robertson M, Barr E, Wahl J, Greaves W (2015) Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. Lancet 386:1537\u20131545","journal-title":"Lancet"},{"key":"2216_CR10","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1097\/SGA.0b013e31818eb70d","volume":"31","author":"SS Roberts","year":"2008","unstructured":"Roberts SS (2008) Assessing ribavirin exposure during pregnancy: the Ribavirin Pregnancy Registry. Gastroenterol Nurs 31:413\u2013417","journal-title":"Gastroenterol Nurs"},{"key":"2216_CR11","first-page":"1745","volume":"61","author":"PW Ament","year":"2000","unstructured":"Ament PW, Bertolino JG, Liszewski JL (2000) Clinically significant drug interactions. Am Fam Physician 61:1745\u20131754","journal-title":"Am Fam Physician"},{"key":"2216_CR12","doi-asserted-by":"publisher","first-page":"133","DOI":"10.2165\/00003088-200746020-00003","volume":"46","author":"H Zhang","year":"2007","unstructured":"Zhang H, Cui D, Wang B, Han YH, Balimane P, Yang Z, Sinz M, Rodrigues AD (2007) Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. Clin Pharmacokinet 46:133\u2013157","journal-title":"Clin Pharmacokinet"},{"key":"2216_CR13","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1111\/j.1472-8206.2000.tb00411.x","volume":"14","author":"MS Benedetti","year":"2000","unstructured":"Benedetti MS (2000) Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol 14:301\u2013319","journal-title":"Fundam Clin Pharmacol"},{"key":"2216_CR14","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.clpt.2003.08.009","volume":"74","author":"SD Hall","year":"2003","unstructured":"Hall SD, Wang Z, Huang S-M, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC (2003) The interaction between St John\u2019s wort and an oral contraceptive. Clin Pharmacol Ther 74:525\u2013535","journal-title":"Clin Pharmacol Ther"},{"key":"2216_CR15","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1111\/j.1528-1157.1999.tb00779.x","volume":"40","author":"C Fattore","year":"1999","unstructured":"Fattore C, Cipolla G, Gatti G, Limido GL, Sturm Y, Bernasconi C, Perucca E (1999) Induction of ethinylestradiol and levonorgestrel metabolism by oxcarbazepine in healthy women. Epilepsia 40:783\u2013787","journal-title":"Epilepsia"},{"key":"2216_CR16","doi-asserted-by":"publisher","first-page":"203","DOI":"10.2165\/00003088-199528030-00003","volume":"28","author":"K Fotherby","year":"1995","unstructured":"Fotherby K (1995) Levonorgestrel. Clinical pharmacokinetics. Clin Pharmacokinet 28:203\u2013215","journal-title":"Clin Pharmacokinet"},{"key":"2216_CR17","unstructured":"Teva Womens Health, Inc. (2016) NORDETTE\u00ae-28 (levonorgestrel and ethinyl estradiol tablets, 0.15\u00a0mg\/0.03\u00a0mg): US presecribing information http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/018782s036lbl.pdf. Accessed on 8 Sept 2016"},{"key":"2216_CR18","unstructured":"Duramed Pharmaceuticals, Inc. (2010) Seasonique (levonorgestrel\/ethinyl estradiol tablets and ethinyl estradiol tablets): US prescribing information (https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021840s008lbl.pdf. Accessed 8 Sept 2016"},{"key":"2216_CR19","unstructured":"AbbVie, Inc. (2016) VIEKIRA PAK\u00ae (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets): US prescribing information http:\/\/www.rxabbvie.com\/pdf\/viekirapak_pi.pdf. Accessed 8 Sept 2016."}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-017-2216-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-017-2216-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,29]],"date-time":"2022-07-29T15:47:14Z","timestamp":1659109634000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-017-2216-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,24]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["2216"],"URL":"https:\/\/doi.org\/10.1007\/s00228-017-2216-4","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,24]]},"assertion":[{"value":"31 October 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"WWY, CBS, LC, HPF, JT, JM, EM, XH, RV, ZG, and JRB are current employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. WLM was an employee of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, at the time the studies were conducted. TR has nothing to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All of the subjects gave their written consent to their participation in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was funded by Merck & Co., Inc.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}